Terms: = Ovarian cancer AND AKAP9, AKAP350, 10142, ENSG00000127914, KIAA0803, Q99996, AKAP450, YOTIAO, PRKA9, HYPERION, MU-RMS-40_16A, CG-NAP
10 results:
1. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract] [Full Text] [Related]
2. Intronic Germline
Fraire CR; Mallinger PR; Hatton JN; Kim J; Dickens DS; Argenta PA; Milanovich S; Hartshorne T; Carey DJ; Haley JS; Urban G; Lee J; Hill DA; Stewart DR; Schultz KAP; Chen KS
JCO Precis Oncol; 2023 Sep; 7():e2300189. PubMed ID: 37883719
[TBL] [Abstract] [Full Text] [Related]
3. Machine Learning Application Identifies Germline Markers of Hypertension in Patients With ovarian cancer Treated With Carboplatin, Taxane, and Bevacizumab.
Polano M; Bedon L; Dal Bo M; Sorio R; Bartoletti M; De Mattia E; Cecchin E; Pisano C; Lorusso D; Lissoni AA; De Censi A; Cecere SC; Scollo P; Marchini S; Arenare L; De Giorgi U; Califano D; Biagioli E; Chiodini P; Perrone F; Pignata S; Toffoli G
Clin Pharmacol Ther; 2023 Sep; 114(3):652-663. PubMed ID: 37243926
[TBL] [Abstract] [Full Text] [Related]
4. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.
Forlani L; De Cecco L; Simeon V; Paolini B; Bagnoli M; Cecere SC; Spina A; Citeroni E; Bignotti E; Lorusso D; Arenare L; Russo D; De Angelis C; Ardighieri L; Scognamiglio G; Del Sesto M; Tognon G; Califano D; Schettino C; Chiodini P; Perrone F; Mezzanzanica D; Pignata S; Tomassetti A
J Exp Clin Cancer Res; 2023 Apr; 42(1):83. PubMed ID: 37041632
[TBL] [Abstract] [Full Text] [Related]
5. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Di Liello R; Arenare L; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Lapresa M; Nardin M; Bogani G; Distefano M; Greggi S; Gargiulo P; Schettino C; Gallo C; Daniele G; Califano D; Perrone F; Pignata S; Piccirillo MC
Int J Gynecol Cancer; 2021 Oct; 31(10):1348-1355. PubMed ID: 34462317
[TBL] [Abstract] [Full Text] [Related]
6. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
[TBL] [Abstract] [Full Text] [Related]
7. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Daniele G; Lorusso D; Scambia G; Cecere SC; Nicoletto MO; Breda E; Colombo N; Artioli G; Cannella L; Lo Re G; Raspagliesi F; Maltese G; Salutari V; Ferrandina G; Greggi S; Baldoni A; Bergamini A; Piccirillo MC; Tognon G; Floriani I; Signoriello S; Perrone F; Pignata S
Gynecol Oncol; 2017 Feb; 144(2):256-259. PubMed ID: 27993479
[TBL] [Abstract] [Full Text] [Related]
8. Synthesis, antiproliferative activity and possible mechanism of action of novel 2-acetamidobenzamides bearing the 2-phenoxy functionality.
Raffa D; Maggio B; Plescia F; Cascioferro S; Raimondi MV; Cancemi G; D'Anneo A; Lauricella M; Cusimano MG; Bai R; Hamel E; Daidone G
Bioorg Med Chem; 2015 Oct; 23(19):6305-16. PubMed ID: 26344588
[TBL] [Abstract] [Full Text] [Related]
9. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast cancer Association Consortium.
Milne RL; Burwinkel B; Michailidou K; Arias-Perez JI; Zamora MP; Menéndez-Rodríguez P; Hardisson D; Mendiola M; González-Neira A; Pita G; Alonso MR; Dennis J; Wang Q; Bolla MK; Swerdlow A; Ashworth A; Orr N; Schoemaker M; Ko YD; Brauch H; Hamann U; ; Andrulis IL; Knight JA; Glendon G; Tchatchou S; ; ; Matsuo K; Ito H; Iwata H; Tajima K; Li J; Brand JS; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Lambrechts D; Peuteman G; Christiaens MR; Smeets A; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Hartman M; Hui M; Yen Lim W; Wan Chan C; Marme F; Yang R; Bugert P; Lindblom A; Margolin S; García-Closas M; Chanock SJ; Lissowska J; Figueroa JD; Bojesen SE; Nordestgaard BG; Flyger H; Hooning MJ; Kriege M; van den Ouweland AM; Koppert LB; Fletcher O; Johnson N; dos-Santos-Silva I; Peto J; Zheng W; Deming-Halverson S; Shrubsole MJ; Long J; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Cox A; Cross SS; Reed MW; Schmidt MK; Broeks A; Cornelissen S; Braaf L; Kang D; Choi JY; Park SK; Noh DY; Simard J; Dumont M; Goldberg MS; Labrèche F; Fasching PA; Hein A; Ekici AB; Beckmann MW; Radice P; Peterlongo P; Azzollini J; Barile M; Sawyer E; Tomlinson I; Kerin M; Miller N; Hopper JL; Schmidt DF; Makalic E; Southey MC; Hwang Teo S; Har Yip C; Sivanandan K; Tay WT; Shen CY; Hsiung CN; Yu JC; Hou MF; Guénel P; Truong T; Sanchez M; Mulot C; Blot W; Cai Q; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Wu AH; Tseng CC; Van Den Berg D; Stram DO; Bogdanova N; Dörk T; Muir K; Lophatananon A; Stewart-Brown S; Siriwanarangsan P; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Shu XO; Lu W; Gao YT; Zhang B; Couch FJ; Toland AE; ; Yannoukakos D; Sangrajrang S; McKay J; Wang X; Olson JE; Vachon C; Purrington K; Severi G; Baglietto L; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Devilee P; Tollenaar RA; Seynaeve C; Czene K; Eriksson M; Humphreys K; Darabi H; Ahmed S; Shah M; Pharoah PD; Hall P; Giles GG; Benítez J; Dunning AM; Chenevix-Trench G; Easton DF
Hum Mol Genet; 2014 Nov; 23(22):6096-111. PubMed ID: 24943594
[TBL] [Abstract] [Full Text] [Related]
10. Association of a common akap9 variant with breast cancer risk: a collaborative analysis.
Frank B; Wiestler M; Kropp S; Hemminki K; Spurdle AB; Sutter C; Wappenschmidt B; Chen X; Beesley J; Hopper JL; ; Meindl A; Kiechle M; Slanger T; Bugert P; Schmutzler RK; Bartram CR; Flesch-Janys D; Mutschelknauss E; Ashton K; Salazar R; Webb E; Hamann U; Brauch H; Justenhoven C; Ko YD; Brüning T; Silva Idos S; Johnson N; Pharoah PP; Dunning AM; Pooley KA; Chang-Claude J; Easton DF; Peto J; Houlston R; ; Chenevix-Trench G; Fletcher O; Burwinkel B
J Natl Cancer Inst; 2008 Mar; 100(6):437-42. PubMed ID: 18334708
[TBL] [Abstract] [Full Text] [Related]
